Wells Fargo Upgrades Relay Therapeutics (RLAY) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Price: $17.69 +1.43%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Eva Fortea Verdejo upgraded Relay Therapeutics (NASDAQ: RLAY) from Equal Weight to Overweight with a price target of $13.00.
For an analyst ratings summary and ratings history on Relay Therapeutics click here. For more ratings news on Relay Therapeutics click here.
Shares of Relay Therapeutics closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: META RIOT PLTR CRWV NFLX SMCI SOFI GOOG IREN HOOD
- Northland on SolarEdge (SEDG): 'Storage remains a bright spot for the Company'
- Wells Fargo Upgrades Duolingo Inc. (DUOL) to Equal Weight
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
